Introduction Many new markers are now available as an aid for decisions about prostate
biopsy for men without prostate cancer and/or to improve risk stratification for men with …

Use of serum prostate-specific antigen (PSA) testing for early detection of prostate cancer
appears to reduce cancer-specific mortality. Due to the limited specificity of PSA for clinically …

Prostate cancer is the most commonly diagnosed cancer in men. At present, patients are
selected for prostate biopsy on the basis of age, serum prostate specific antigen (PSA), and …

Objectives: To investigate whether current literature gives the answer to the questions how
biopsies of the prostate should be taken and when they should be taken in order to …

Abstract Background The 4Kscore combines measurement of four kallikreins in blood with
clinical information as a measure of the probability of significant (Gleason≥ 7) prostate …

Historically, prostate biopsy was performed because of a prostate-specific antigen (PSA)
level exceeding a specific threshold or suspicious findings on digital rectal examination …

Study Type–Diagnosis (validating cohort) Level of Evidence 1b What's known on the
subject? and What does the study add? The European Randomized study of Screening for …

In recent years, several new biomarkers supplementing the role of prostate-specific antigen
(PSA) have become available for men with prostate cancer. Although widely used in an ad …

With the recent publication of its final grade D recommendation against prostate-specific
antigen (PSA)–based screening [1], the influential US Preventive Services Task Force …

Background Recognizing the limitations of prostate-specific antigen (PSA) screening and
the morbidity of prostate biopsies, several blood-and urine-based biomarkers have been …